Y-90を用いたRadioembolizationの現状について
鈴木ありさ
原発性肝腫瘍、および転移性肝腫瘍に対するRadioembolizationは2002年にFDAに認可されて以来、爆発的に全米に広がっており、現状ではRadioembolizationを提供できない施設はIO（Interventional Oncology）に弱い施設、と見られてしまうほど一般化している。米国での導入の実際を簡潔に記した。
Radioembolization for primary and metastatic hepatic tumor is significantly increasing in numbers in locations since 2002. Radioembolization provider has to certified an“Authorized User” from NRC. AU can be Radiation Oncologist, Nuclear Medicine or ACGME Interventional Radiology fellowship gradurates. Efficacy is proven to be more than conventional／DEB-TACE and complications are less than conventional treatment. The key feature of the preparation embolization is isolate proper／right／left hepatic arteries, which is identical technique to the transarterial reservoir placement.
